Genomic Determinants of Antimicrobial Resistance: Integrating Molecular Mechanisms, Diagnostic Technologies, and Artificial Intelligence for Precision Treatment
Toheeb Olaniyi Falakin
*
Department of Aquaculture and Aquatic Sciences, Kentucky State University, Frankfort, Kentucky, United States of America.
Victoria Ifeyinwa Uwakwe
Department of Biology, Bemidji State University, Minnesota, United States of America.
Nana Akua Fosua Lawson Darko
School of Optometry and Vision Sciences, University of Cape Coast, Cape Coast, Ghana.
Felix Darko
Department of Cell Biology, University of Oklahoma Health Campus, Oklahoma City, OK 73104, United States of America.
Esther Sarpong
Department of Biomedical Sciences, University for Development Studies, Tamale, Northern Region, Ghana.
Kwadwo Owusu-Boateng
School of Medicine, University for Development Studies, Tamale, Northern Region, Ghana.
*Author to whom correspondence should be addressed.
Abstract
Antimicrobial resistance (AMR) remains a major global health challenge, complicating infection management and increasing the risk of treatment failure. Although conventional antimicrobial susceptibility testing guides treatment selection, delays in obtaining results can hinder timely targeted therapy. Advances in bacterial genomics, molecular diagnostics, and artificial intelligence (AI) offer opportunities to improve resistance detection and support precision antimicrobial therapy. However, a persistent gap remains between identifying genomic resistance determinants, translating them into reliable diagnostic interpretations, and applying these findings to individual treatment decisions. This review critically synthesizes evidence on the genomic architecture of AMR, emerging diagnostic technologies, AI-assisted interpretation, and their integration into clinical practice. It examines major resistance mechanisms, including acquired resistance genes, chromosomal mutations, mobile genetic elements, and regulatory changes, alongside whole-genome sequencing, molecular detection, and phenotypic susceptibility testing. It further evaluates machine learning applications in resistance prediction and clinical decision support, highlighting limitations associated with genotype–phenotype discordance, dataset representativeness, model generalisability, diagnostic uncertainty, infrastructure, and clinical validation. Ethical governance, regulatory oversight, and equitable implementation are also considered. An integrative conceptual framework is proposed linking biological determinants, diagnostic evidence, computational interpretation, clinical decision-making, and patient outcomes. The framework emphasizes that genomic detection and AI predictions require contextual interpretation and clinical oversight. Ultimately, translating these innovations into effective precision antimicrobial therapy requires mechanistic understanding, robust validation, clinical integration, sustainable implementation, and demonstrated improvements in patient outcomes.
Keywords: Antimicrobial resistance, antimicrobial resistance genes, bacterial genomics, whole-genome sequencing, molecular diagnostics, antimicrobial susceptibility testing, artificial intelligence, machine learning, precision antimicrobial therapy